18699-02-0
Chemical Structure
Actarit
Synonym(s): 4-Acetylaminophenylacetic acid; MS-932
- CAS No.: 18699-02-0
- Formula:C10H11NO3
- Molecular Weight:193.20
IUPAC Name: 2-(4-acetamidophenyl)acetic acid
InChIKey: MROJXXOCABQVEF-UHFFFAOYSA-N
SMILES: O=C(C)NC(C=C1)=CC=C1CC(O)=O
Biological Activity: Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII)-induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Actarit | 99.58% | Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII)-induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Actarit (Standard) | ≥98% | Actarit (Standard) is the analytical standard of Actarit. This product is intended for research and analytical applications. Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII)-induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kawai K, et al. Suppressive effects of 4-acetylaminophenylacetic acid (actarit) on experimental autoimmune encephalomyelitis in rats. Immunopharmacology. 1998 May;39(2):127-38. [Content Brief]
- [2]. Fujisawa H, et al. Effect of actarit on type II collagen-induced arthritis in mice. Arzneimittel-forschung, 01 Jan 1994, 44(1):64-68. [Content Brief]
- [3]. Ghislat G, et al. Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit. Biomolecules. 2020 Nov 19;10(11):1570. [Content Brief]
- [4]. Fujisawa H, et al. Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer's patches. Int J Immunopharmacol. 1995 Jul;17(7):611-7. [Content Brief]
Keywords
